IGEN BIOLAB is a biotechnology company that pioneered the development of microbiome modulators, which are bioactive therapies that benefit human health by altering the composition and activities of microbial communities in the body to regulate host pathways.

IGEN BIOLAB focuses on microbiome modulators that impact infection, immunity, and metabolic disease. The company is currently conducting five clinical trials and additional discovery efforts. Recent scientific discoveries are forcing the industry to rethink how changes in the microbiome influence human health, and IGEN BIOLAB is amongst the first companies to elucidate microbiome discoveries.


IGEN BIOLAB has developed a patented approach to generate small molecules, biological peptides and symbiotic candidates for products that modulate human microbes and microorganisms that contribute to health or disease. This approach is based on understanding the composition and role of the microbial community in healthy and diseased conditions. These profiles also form the basis for the discovery of new biomarkers used for the development of new drugs and diagnostics.


IGEN BIOLAB is involved in a number of strategic collaborations for the discovery and development of microbiome modulating therapies. These partnerships further validate the broad utility of IGEN BIOLAB’s Microbiome Science capabilities and tools to help discover and develop product candidates that modulate the interactions of microbe microorganisms and microorganisms in multiple disease areas for its partners.

IGEN BIOLAB works with a wide network of researchers – from academic laboratories to multinational biopharmacy and nutrition companies – to support discovery aimed at identifying new targets and mechanisms of the disease. IGEN BIOLAB, a unique set of scientific microbiology capabilities and tools that further the undertaking of metagenomic trials, validated SOPs for bio-sample handling and genomic preparation, as well as integrated bioinformatics aimed at the reproducible identification of microbial community health targets and their effects.


Patients suffering from serious illnesses, which are often life-threatening, are at the center of our efforts. This approach is the essential condition for the success of our work, in which not only our employees participate, but so do our collaborators and external collaborators.

Our commitment to medical progress goes hand-in-hand with our commitment to our patients: everyone who could benefit from our results should have the opportunity to do so. This promise extends to doctors and to the whole community of those involved in patient care.

Functional protein immunotherapies help doctors and other health professionals provide high-quality medical nutritional care and help patients improve.

IGEN BIOLAB staff work every day to deliver on this promise.

From our point of view, IGEN BIOLAB’s portfolio of projects represents a promise in itself. Not only does it embody the company’s significant potential, but also new possibilities and new hope for hundreds of thousands of people around the world who are suffering from oncological and degenerative diseases.

IGEN BIOLAB is working for them in terms of new approaches to Medicine, discovering a variety of biological activities of plant and animal origin, which entails an important potential in terms of therapy and preventive diagnosis.

The result? Our growth prospects are equal to our ability to offer services based on our scientific potential.